Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.

EP: 1.The Role of the HER2 Receptor in Breast Cancer

EP: 2.Necessary Tests After a Diagnosis of Breast Cancer

EP: 3.Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

EP: 4.Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist

EP: 5.Guideline-Recommended Treatments for HER2-Positive Metastatic Breast Cancer

EP: 6.Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

Now Viewing

EP: 7.Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

EP: 8.How HER2 Targeted Therapies Fight HER2-Positive Metastatic Breast Cancer

EP: 9.Imaging Scans for Assessing HER2-Positive Breast Cancer Progression and Treatment Response

EP: 10.Potential Severe Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

EP: 11.Collaborating With Your Oncology Care Team to Manage Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

Related Videos

Related Content

Advertisement

June 12th 2025

Beyond Treatment: How Support Groups Helped Me Embrace My New Normal

Patti McGee

Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.

February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

June 10th 2025

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

Kristie L. Kahl

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.

December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

June 4th 2025

Dealing with Insensitivity After Breast Cancer Surgery

Bonnie Annis

Breast cancer surgery can disfigure the body in some way, and often the scars are more than skin deep, which may worsen by the actions of others.

June 3rd 2025

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

Gina Mauro

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

Related Content

Advertisement

June 12th 2025

Beyond Treatment: How Support Groups Helped Me Embrace My New Normal

Patti McGee

Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.

February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

June 10th 2025

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

Kristie L. Kahl

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.

December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

June 4th 2025

Dealing with Insensitivity After Breast Cancer Surgery

Bonnie Annis

Breast cancer surgery can disfigure the body in some way, and often the scars are more than skin deep, which may worsen by the actions of others.

June 3rd 2025

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

Gina Mauro

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.